Blood Reviews最新文献_第7页

Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol 单倍体骨髓移植+ 3 + 5天移植后使用环磷酰胺:热那亚方案

IF 7.4 2区医学

Blood Reviews Pub Date : 2023-11-01 DOI: 10.1016/j.blre.2022.101031

Anna Maria Raiola , Emanuele Angelucci , Simona Sica , Andrea Bacigalupo

{"title":"Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol","authors":"Anna Maria Raiola , Emanuele Angelucci , Simona Sica , Andrea Bacigalupo","doi":"10.1016/j.blre.2022.101031","DOIUrl":"10.1016/j.blre.2022.101031","url":null,"abstract":"<div><p><span><span>We report 634 patients who underwent unmanipulated haploidentical (HAPLO) bone marrow transplantation (BMT) in two Centers. The diagnosis was </span>acute myeloid leukemia (AML) (</span><em>n</em><span> = 251), acute lymphoblastic leukemia (ALL)(</span><em>n</em><span> = 107), myelodysplastic syndrome and myelofibrosis (MDS + MF) (</span><em>n</em><span> = 125) and chronic lymphoproliferative disorders (</span><em>n</em><span><span> = 151). Median age was 52 years (16–74). Graft versus host disease (GvHD) prophylaxis was intravenous </span>cyclosporin<span><span><span> (CSA) starting on day 0, oral mycophenolate on day +1, and post-transplant </span>cyclophosphamide<span><span><span> (PTCY) on days +3 + 5. Primary graft failure was seen in 23 patients (3,6%); 17 /23 (74%) were rescued with second HAPLO graft, and were alive at one year. The cumulative incidence of </span>acute GvHD grade II-IV was 29% and 3% for grade III-IV; the cumulative incidence of moderate severe </span>chronic GvHD was 23%: older donor and patients age were significant predictors of both acute and chronic GvHD. The overall non relapse mortality (NRM) at 2 years was 19%: 8%, 21% and 30% </span></span>in patients<span><span> aged <40, 41–60 > 60 years. Disease free survival (DFS) at 5 years was 64% for </span>acute leukemia in first remission, 51% for acute leukemia CR2, 25% for acute leukemia advanced disease and 49% for MDS/MPN.</span></span></span></p><p>We confirm, on a relatively large number of patients, that unmanipulated HAPLO BMT with PTCY on days +3 + 5, mostly after a myeloablative conditioning regimen, is followed by a low incidence of graft failure and grade III-IV GvHD; moderate severe chronic GvHD is 23% and NRM at 2 years 19%; 5 year DFS is influenced by remission status of the underlying disease.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40485727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS) 骨髓增生异常综合征/肿瘤(MDS)的分类、风险分层和反应评估:代表国际MDS协会(icMDS)的最新报告

IF 7.4 2区医学

Blood Reviews Pub Date : 2023-11-01 DOI: 10.1016/j.blre.2023.101128

Maximilian Stahl , Jan Philipp Bewersdorf , Zhuoer Xie , Matteo Giovanni Della Porta , Rami Komrokji , Mina L. Xu , Omar Abdel-Wahab , Justin Taylor , David P. Steensma , Daniel T. Starczynowski , Mikkael A. Sekeres , Guillermo Sanz , David A. Sallman , Gail J. Roboz , Uwe Platzbecker , Mrinal M. Patnaik , Eric Padron , Olatoyosi Odenike , Stephen D. Nimer , Aziz Nazha , Amer M. Zeidan

{"title":"Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)","authors":"Maximilian Stahl , Jan Philipp Bewersdorf , Zhuoer Xie , Matteo Giovanni Della Porta , Rami Komrokji , Mina L. Xu , Omar Abdel-Wahab , Justin Taylor , David P. Steensma , Daniel T. Starczynowski , Mikkael A. Sekeres , Guillermo Sanz , David A. Sallman , Gail J. Roboz , Uwe Platzbecker , Mrinal M. Patnaik , Eric Padron , Olatoyosi Odenike , Stephen D. Nimer , Aziz Nazha , Amer M. Zeidan","doi":"10.1016/j.blre.2023.101128","DOIUrl":"10.1016/j.blre.2023.101128","url":null,"abstract":"<div><p>The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we summarize these developments. We first critically examine the updated World Health Organization (WHO) classification and the International Consensus Classification (ICC) of MDS. We then compare traditional and molecularly based risk MDS risk assessment tools. Lastly, we discuss limitations of criteria in measuring therapeutic benefit and highlight how the International Working Group (IWG) 2018 and 2023 response criteria addressed these deficiencies and are endorsed by the icMDS. We also address the importance of patient centered care by discussing the value of quality-of-life assessment. We hope that the reader of this review will have a better understanding of how to classify MDS, predict clinical outcomes and evaluate therapeutic outcomes.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10597745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Preservation of fertility in female patients with hematologic diseases 女性血液病患者生育能力的保存

IF 7.4 2区医学

Blood Reviews Pub Date : 2023-11-01 DOI: 10.1016/j.blre.2023.101115

Marika Bini Antunes , Sara Pinto Cardeal , Manuel Magalhães , Emídio Vale-Fernandes , Márcia Barreiro , Rosália Sá , Mário Sousa

{"title":"Preservation of fertility in female patients with hematologic diseases","authors":"Marika Bini Antunes , Sara Pinto Cardeal , Manuel Magalhães , Emídio Vale-Fernandes , Márcia Barreiro , Rosália Sá , Mário Sousa","doi":"10.1016/j.blre.2023.101115","DOIUrl":"10.1016/j.blre.2023.101115","url":null,"abstract":"<div><p><span><span>Recent developments of assisted reproduction techniques<span> turned possible to avoid the infertility consequences of oncologic treatments, but </span></span>fertility preservation<span> (FP) has been somewhat neglected in women with hematologic diseases undergoing gonadotoxic treatments. For these specific cases, the current options for FP include the </span></span>cryopreservation<span> of embryos, mature oocytes and ovarian tissue, and oocyte in-vitro maturation. We intend to make patients and clinicians aware of this important and relevant issue, and provide hematologists, assisted reproduction physicians and patients, with updated tools to guide decisions for FP. The physicians of the units responsible for female FP should always be available to decide on the best-individualized FP option in strict collaboration with hematologists. With a wide range of options for FP tailored to each case, a greater level of training and information is needed among clinicians, so that patients proposed to gonadotoxic treatments can be previously advised for FP techniques in hematological conditions.</span></p></div><div><h3>Abbreviated abstract</h3><p>Recent developments of assisted reproduction techniques turned possible to preserve the fertility of women with hematologic diseases undergoing gonadotoxic treatments.</p><p>Current options for fertility preservation in women with hematologic diseases are presented.</p><p>It is imperative to offer fertility preservation to all women before starting any gonadotoxic treatment and in some cases after treatment.</p><p>Fertility preservation methods enable to later achieve the desired pregnancy</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9974628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution 靶向髓系恶性肿瘤细胞凋亡失调-治疗革命的希望

IF 7.4 2区医学

Blood Reviews Pub Date : 2023-11-01 DOI: 10.1016/j.blre.2023.101130

Enrico Santinelli , Maria Rosaria Pascale , Zhuoer Xie , Talha Badar , Maximilian F. Stahl , Jan P. Bewersdorf , Carmelo Gurnari , Amer M. Zeidan

{"title":"Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution","authors":"Enrico Santinelli , Maria Rosaria Pascale , Zhuoer Xie , Talha Badar , Maximilian F. Stahl , Jan P. Bewersdorf , Carmelo Gurnari , Amer M. Zeidan","doi":"10.1016/j.blre.2023.101130","DOIUrl":"10.1016/j.blre.2023.101130","url":null,"abstract":"<div><p><span>In recent years, the therapeutic landscape of myeloid malignancies<span> has been completely revolutionized by the introduction of several new drugs<span>, targeting molecular alterations or pathways crucial for leukemia cells<span> survival. Particularly, many agents targeting apoptosis have been investigated in both pre-clinical and clinical studies. For instance, </span></span></span></span>venetoclax<span><span>, a pro-apoptotic agent active on BCL-2 signaling, has been successfully used in the treatment of </span>acute myeloid leukemia<span> (AML). The impressive results achieved in this context have made the apoptotic pathway an attractive target also in other myeloid neoplasms, translating the experience of AML. Therefore, several drugs are now under investigation either as single or in combination strategies, due to their synergistic efficacy and capacity to overcome resistance.</span></span></p><p>In this paper, we will review the mechanisms of apoptosis and the specific drugs currently used and under investigation for the treatment of myeloid neoplasia, identifying critical research necessities for the upcoming years.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10183386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Does PTCY increase the risk of infections? PTCY会增加感染的风险吗?

IF 7.4 2区医学

Blood Reviews Pub Date : 2023-11-01 DOI: 10.1016/j.blre.2023.101092

Malgorzata Mikulska , Claudia Bartalucci , Anna Maria Raiola , Chiara Oltolini

引用次数: 1

Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management HLA同种免疫引起的血小板输注难治性：机制和管理的演变范式。

IF 7.4 2区医学

Blood Reviews Pub Date : 2023-11-01 DOI: 10.1016/j.blre.2023.101135

Sandhya R. Panch , Li Guo , Ralph Vassallo

引用次数: 0

Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond 将移植后环磷酰胺扩大到匹配的非亲属供体移植及其他

IF 7.4 2区医学

Blood Reviews Pub Date : 2023-11-01 DOI: 10.1016/j.blre.2023.101053

Mahasweta Gooptu , Javier Bolaños-Meade , John Koreth

引用次数: 0

The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment 核心结合因子急性髓系白血病的核心概念:当前对预后和治疗的考虑

IF 7.4 2区医学

Blood Reviews Pub Date : 2023-11-01 DOI: 10.1016/j.blre.2023.101117

Christina Darwish , Kyle Farina , Douglas Tremblay

{"title":"The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment","authors":"Christina Darwish , Kyle Farina , Douglas Tremblay","doi":"10.1016/j.blre.2023.101117","DOIUrl":"10.1016/j.blre.2023.101117","url":null,"abstract":"<div><p><span><span><span>Core binding factor </span>acute myeloid leukemia<span> (CBF AML), defined by t(8;21) or inv(16), is a subset of favorable risk AML. Despite its association with a high complete </span></span>remission rate<span><span> after induction and relatively good prognosis overall compared with other subtypes of AML, relapse risk after induction chemotherapy remains high. Optimizing </span>treatment<span> planning to promote recurrence free survival and increase the likelihood of survival after relapse is imperative to improving outcomes. Recent areas of research have included evaluation of the role of </span></span></span>gemtuzumab<span> in induction and consolidation, the relative benefit of increased cycles of high dose cytarabine<span><span> in consolidation, the utility of hypomethylating agents<span> and kinase inhibitors, and the most appropriate timing of </span></span>stem cell transplant. Surveillance with measurable residual disease testing is increasingly being utilized for monitoring disease in remission, and ongoing investigation seeks to determine how to use this tool for early identification of patients who would benefit from proceeding to transplant. In this review, we outline the current therapeutic approach from diagnosis to relapse while highlighting the active areas of investigation in each stage of treatment.</span></span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9914173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review 血管性血友病合并大量月经出血妇女术中出血的预防和治疗策略:系统综述

IF 7.4 2区医学

Blood Reviews Pub Date : 2023-11-01 DOI: 10.1016/j.blre.2023.101131

H.P. Eising , M.C. Punt , J.C. Leemans , M.Y. Bongers

{"title":"Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review","authors":"H.P. Eising , M.C. Punt , J.C. Leemans , M.Y. Bongers","doi":"10.1016/j.blre.2023.101131","DOIUrl":"10.1016/j.blre.2023.101131","url":null,"abstract":"<div><h3>Background</h3><p>Optimal peri-operative management for women with Von Willebrand disease<span> (VWD) and heavy menstrual bleeding (HMB) remains undetermined.</span></p></div><div><h3>Aim and methods</h3><p>To evaluate (pre)operative management in relation to (post)operative bleeding after endometrial ablation<span> (EA) and hysterectomy in VWD women with HMB by performing a database search between 1994 and 2023.</span></p></div><div><h3>Results</h3><p>Eleven cohort studies<span> and 1 case-report were included, of overall ‘low’ quality, describing 691 operative procedures. Prophylaxis (Desmopressin, clotting factor concentrates or tranexamic acid) to prevent bleeding was described in 100% (30/30) of EA procedures and in 4% (24/661) of hysterectomies. Bleeding complications despite prophylaxis were described in 13% (3/24) of hysterectomies vs 0% (0/30) in EA.</span></p></div><div><h3>Conclusion</h3><p>VWD women often seem to experience bleeding complications during hysterectomy and all women with VWD received preprocedural hemostatic agents during EA, indicating potential under- and overdosing of current prophylactic strategies. Prospective studies are needed to determine the optimal (pre)operative strategy for gynecological surgical procedures in women with VWD.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10270165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PTCy: The “new” standard for GVHD prophylaxis PTCy: GVHD预防的“新”标准

IF 7.4 2区医学

Blood Reviews Pub Date : 2023-11-01 DOI: 10.1016/j.blre.2023.101096

Andrea Bacigalupo , Richard Jones

引用次数: 0